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Science was the center of his family life, and his fam-
ily was extensive. Included were his dear wife Marge and 
his four sons, and de facto members who had the privilege 
of working with him. Our gathering sites were exclusively 
his home in Woodbridge and the hospital. We shared the 
chores with little notice of hours and pay. Our shared goals 
were Aaron’s success in research and the development of 
an outstanding department. In modern business strategy 
terms, Aaron invested himself in human capital, the key to 
greatest success.
The integration of Aaron’s science cum family is well 
depicted in the picture of his son Michael holding hundreds 
of bovine pineal glands The picture was taken in Aaron’s 
office, with the boy standing on a chair. It was not unusual 
for the Lerner boys to come in on Sunday to wait and play 
where a huge blackboard was handy for math equations or 
chemical structures. Its ledge bore the sliding plastic chemi-
cal units of MSH being gradually identified and linked togeth-
er. When on the telephone with a colleague and competitor 
in working out the structure of MSH, Aaron heard the latest 
linkage; there was a stunned silence, he reflected, and after a 
moment, quietly showing his great respect for his colleague 
and confidence in himself, said, “Then there are two MSH’s.” 
Indeed there are: alpha and beta.
The family spirit lives on in the persons of his sons, Michael 
and Ethan, both distinguished, innovative dermatologists. The 
imprint of the family Lerner is indelible, unable to be erased 
by time and distance. The department he created and its ded-
ication to science live on as well, under the leadership of his 
successor, Rick Edelson.
In his precious free moments Aaron was a collector, filling 
his home with a historical series of calculators and gifts of 
frog memorabilia. His one public hero was Albert Einstein, 
and he had sheets of Einstein postal stamps in his collection.
Like Einstein, Aaron Lerner was an extraordinary human 
being never to be forgotten.
Marie-Louise T. Johnson
Yale University School of Medicine, New Haven, Connecticut, USA
Aaron Lerner’s Legacy at Yale University
The Yale Department of Dermatology is the “house that 
Aaron built.” That rewording of the age-old description of 
Yankee Stadium as the “house that [Babe] Ruth built” is 
quite fitting, because his most enduring legacy at Yale is the 
creation of a culture in which students, residents, fellows, 
and faculty are encouraged to “swing for the fences,” striv-
ing to follow his example of tackling big ideas and expan-
sive goals. Along with many, I have been deeply affected 
by Aaron through four decades, dating from my days as a 
Yale Medical School student performing research in the der-
matology department to my research fellowship in the der-
matology branch of the National Cancer Institute when he 
served as scientific advisor, to my faculty years at Columbia 
when he kept close watch over me, to my past 21 years as 
his successor as chair of Yale’s dermatology department. 
Running toward and then behind someone for so long, 
across all grades of terrain, gives me a cherished view of 
his comfortable gait and the giant steps that he took for and 
through the field.
Back in the late 1960s, the stampede into dermatology res-
idencies was not yet even envisioned as a national phenom-
enon but, thanks to Aaron and the faculty he had attracted, 
it was already well developed at Yale. In my 1970 graduat-
ing class alone, Len Milstone, Anne Lucky, and Rob Stern, 
in addition to myself, were stimulated to initiate our careers 
in the specialty. Aaron’s faculty in those days included four 
faculty members (himself, Irwin Braverman, Joe McGuire, 
and Marty Carter) who would each serve as president of the 
Society for Investigative Dermatology, as well as Sid Klaus, 
who would later shape Israeli dermatology as the chairman at 
Hadassah Medical Center in Jerusalem. Beyond being highly 
regarded as a center of excellence, the Yale Department of 
Dermatology was, per capita (faculty member), in the very 
top echelon of the Medical Center hierarchy.
I vividly remember being stunned by Aaron’s softly stated 
proclamation that there were still many biologically impor-
tant molecules waiting to be discovered. He thought bigger 
and with more confidence than anyone I had ever met. The 
audacity of that declaration of opportunity, emanating from 
such a soft-spoken and apparently unassuming professor, 
became indelibly imprinted on all of us. He was not only 
imploring us to shoot high and to our limits but also firmly 
admonishing us to not sell ourselves short. The accomplish-
ments of his dermatologic progeny can so readily be traced 
back to his quiet exuberance and confidence.
He inspired generations of students and faculty to think 
bold thoughts, to pursue outsized goals, to not be afraid to 
fail, and to not be afraid to swing for the fences. Swinging 
and missing then becomes a sign of strength of purpose 
and an absolute prerequisite for major success. Among the 
many, many metaphoric trees he planted in this department, 
it was his productively directed audacity that is, in my view, 
his major legacy, the one that most significantly shaped our 
department’s collective identity.
From the day that I was invited to succeed Aaron as chair, 
he was exceptionally supportive. For 10 years, from his 
maintained office, strategically placed in the midst of the 
departmental research enterprise, he provided sage coun-
sel to me on virtually all issues. He took great pride in our 
sustained growth and remained a vibrant force in our midst 
until weeks before his passing. He and his devoted wife, 
Millie, regularly attended nearly all our departmental func-
tions and honorary lectures. In early December of 2006, he 
participated in the annual holiday party, not as a guest but 
as the proud founding father of our clan.
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Aaron’s attention to detail was as legendary as his focus 
on global thoughts. At that most recent holiday party he 
expressed his pleasure that we had continued his tradition 
of the huge shrimp bowl that had been the congregational 
centerpiece of his own parties. He recognized that the rock 
music and size of the event were relatively trivial departures 
from the past. He was obviously pleased that, despite stylis-
tic difference, the spirit and substance so important to him 
had not changed one iota.
Aaron embraced, and was a closely collaborating agent 
of, ongoing departmental evolution. He continually updat-
ed his own list of all faculty members, in both our own and 
other departments of dermatology, who had emanated from 
our training programs and followed their careers closely. 
He was consulted regularly and contributed substantially 
to the modifications we made in the postdoctoral training 
grant that he had originally achieved. This is just one of the 
numerous examples of how so many of our recent successes 
can be traced directly to his advice.
Well before the term was in vogue, Aaron was a pioneering 
“translational scientist.” Many of his scientific contributions 
have had lasting major clinical applications. The stories of 
cryoglobulins, melanocyte-stimulating hormone, melatonin, 
and psoralens continue to expand into new vistas. He was 
one of the first to recognize that the clinical manifestations of 
malignant cells—his focus being on melanoma—commonly 
reflect the biologic features of the normal cells of origin. This 
was a major lesson from him that my own group has attempt-
ed to amplify in our studies of human T-cell lymphomas and 
that has now been extended to all categories of cancer. Once 
again, Aaron was a trailblazer, far ahead of the curve.
We at Yale will miss him deeply, on every personal and 
professional level. We, and our own successors, will always 
be so very indebted to him for his having given us the chance 
to stand on his shoulders in the house that Aaron built.
Richard Edelson
Department of Dermatology, Yale Cancer Center, Yale University 
School of Medicine, New Haven, Connecticut, USA
Current Understanding and Future Implications of 
the Circadian Uses of Melatonin, a Neurohormone 
Discovered by Aaron B. Lerner
Melatonin is related to circadian rhythms as both a dependent 
and an independent variable. As a dependent variable, the 
dim light melatonin onset (DLMO)—the time when melato-
nin levels rise in the evening—is the most widely used mark-
er for the timing of endogenous circadian rhythms in human 
chronobiology research and will soon be used in the clinic 
as well. The time interval (in hours) between the DLMO and 
mid-sleep is the phase angle difference (PAD) between them. 
PAD is expected to become an important marker for inter-
nal circadian alignment/misalignment. A PAD study recently 
reported a substantial circadian component of winter depres-
sion (seasonal affective disorder, or SAD) and its treatment 
with circadian phase-resetting agents. Although appropri-
ately timed bright light is the treatment of choice for SAD, it 
can also be treated with low-dose melatonin, an independent 
variable optimally administered for most patients in the after-
noon/evening, in order for this chemical signal of nighttime 
darkness to cause a corrective phase advance. Induction of 
a therapeutic phase delay, for example, in the treatment of 
advanced sleep phase syndrome (ASPS), requires that mela-
tonin be administered in the morning. Melatonin is the treat-
ment of choice for totally blind people with free-running cir-
cadian rhythms (blind free-runners, or BFRs).
What if Aaron Lerner had lived in the days of Walter 
Cannon (Cannon, 1939), or even Claude Bernard (Bernard, 
1927), and led his team to discover melatonin decades 
before 1958 (Lerner et al., 1959)? There might have been 
fewer years between melatonin’s identification and the dis-
covery of its physiological role in circadian homeostasis. On 
the other hand, perhaps work that began in the decade or 
two following Dr. Lerner’s discovery (Daan and Pittendrigh, 
1976; DeCoursey, 1960) was also necessary. In any event, we 
can now discern the broad outlines of melatonin’s circadian 
properties. A more complete understanding of Dr. Lerner’s 
melatonin legacy may require some speculations based on 
what is known at the present time.
Other monographs in this volume and elsewhere will cover 
the events around Dr. Lerner’s discoveries, as well as proper-
ties of melatonin that do not relate to the circadian system 
of humans. A review of work by others in the circadian field 
was recently published (Wirz-Justice, 2006). Noncircadian 
properties generally depend on supraphysiological levels of 
melatonin. Therefore, some potentially therapeutic uses of 
this safe and nonabusable neurohormone will not be consid-
ered here.
Physiological levels of melatonin appear to be sufficient 
for causing circadian phase shifts, as well as for providing 
an ideal biological marker for the phase of the endogenous 
circadian pacemaker (Lewy et al., 1992, 1998, 2005). Studies 
of the circadian aspects of melatonin have resulted in thera-
peutic uses and advanced our understanding of melatonin 
physiology (Lewy et al., 2006b). Perhaps uniquely, administra-
tion of even high doses of melatonin does not cause negative 
feedback inhibition on the level of its production (Matsumoto 
et al., 1997). Therefore, in the original formulations of homeo-
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